Cargando…

Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study

INTRODUCTION: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML. The aim of this dose-finding part of this trial was to evaluate feasibility and safety of azacitidine co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krug, Utz, Koschmieder, Anja, Schwammbach, Daniela, Gerss, Joachim, Tidow, Nicola, Steffen, Björn, Bug, Gesine, Brandts, Christian H., Schaich, Markus, Röllig, Christoph, Thiede, Christian, Noppeney, Richard, Stelljes, Matthias, Büchner, Thomas, Koschmieder, Steffen, Dührsen, Ulrich, Serve, Hubert, Ehninger, Gerhard, Berdel, Wolfgang E., Müller-Tidow, Carsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534078/ https://www.ncbi.nlm.nih.gov/pubmed/23300745 http://dx.doi.org/10.1371/journal.pone.0052695

Ejemplares similares

Construction and Application of an Inducible System for Homogenous Expression Levels in Bulk Cell Lines
por: Yu, Jun, et al.
Publicado: (2009)

Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
por: Ruhnke, Leo, et al.
Publicado: (2023)

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia
por: Schemionek, Mirle, et al.
Publicado: (2015)

A Limited Role for the Cell Cycle Regulator Cyclin A1 in Murine Leukemogenesis
por: Bäumer, Nicole, et al.
Publicado: (2015)

Mutations of the EPHB6 Receptor Tyrosine Kinase Induce a Pro-Metastatic Phenotype in Non-Small Cell Lung Cancer
por: Bulk, Etmar, et al.
Publicado: (2012)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
por: Kaifie, A., et al.
Publicado: (2016)

UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
por: Georgi, Julia-Annabell, et al.
Publicado: (2023)

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial
por: Röllig, Christoph, et al.
Publicado: (2021)

Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
por: Stasik, Sebastian, et al.
Publicado: (2022)

Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML
por: Cremer, Anjali, et al.
Publicado: (2023)

P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT
por: Cremer, Anjali, et al.
Publicado: (2023)

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
por: Kunadt, Desiree, et al.
Publicado: (2022)

Inflammation and anti-inflammatory approaches in myeloproliferative neoplasm
por: Koschmieder, Steffen, et al.
Publicado: (2018)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Is Treatment for Cytopenic Myelofibrosis Still an Unmet Clinical Need?
por: Caduc, Madeline J., et al.
Publicado: (2023)

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia
por: Eckardt, Jan-Niklas, et al.
Publicado: (2021)

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms
por: Chatain, Nicolas, et al.
Publicado: (2020)

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
por: Schliemann, Christoph, et al.
Publicado: (2016)

Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD
por: Stasik, Sebastian, et al.
Publicado: (2022)

Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells
por: Lipka, Daniel B., et al.
Publicado: (2012)

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
por: Middeke, Jan M., et al.
Publicado: (2022)

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
por: Hanoun, Maher, et al.
Publicado: (2022)

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
por: Berdel, Andrew F., et al.
Publicado: (2022)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2016)

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
por: Bérard, Emilie, et al.
Publicado: (2022)

Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2018)

Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options
por: Lang, Fabian, et al.
Publicado: (2017)

Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2019)

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer
por: Müller-Tidow, C, et al.
Publicado: (2001)

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
por: Baumeister, Julian, et al.
Publicado: (2021)

Workflow to improve patient recruitment for clinical trials within hospital information systems – a case-study
por: Dugas, Martin, et al.
Publicado: (2008)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
por: Waclawiczek, Alexander, et al.
Publicado: (2023)

Surface Plasmon Enhanced Evanescent Wave Laser Linac
por: Koschmieder, T H
Publicado: (1993)

Evanescent Wave Acceleration Of Electrons From 0.2-c To 0.95-c
por: Koschmieder, T H
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_gqi11rgl59dviqvj6fssk3rfi5